Qi Li

Shijiazhuang, 050018, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Evaluation of capabilities of Chinese provincial veterinary laboratories in detection of African swine fever virus: a proficiency testing program.

Evaluation of capabilities of Chinese provincial veterinary laboratories in detection of African swine fever virus: a proficiency testing program.

Journal: Frontiers in veterinary science

Published: January 11, 2026

Trojan Horse Effect of Biologically Aged Microplastics-An Intracellular Carrier of LPS for Licensing Noncanonical Inflammasome Activation.

Trojan Horse Effect of Biologically Aged Microplastics-An Intracellular Carrier of LPS for Licensing Noncanonical Inflammasome Activation.

Journal: Environmental science & technology

Published: December 29, 2025

Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.

Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.

Journal: BMC infectious diseases

Published: September 10, 2025

Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].

Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].

Journal: Vaccine

Published: July 17, 2024

Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants.

Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants.

Journal: Molecular pharmaceutics

Published: June 26, 2024

Extracellular Vesicle-Based mRNA Therapeutics and Vaccines.

Extracellular Vesicle-Based mRNA Therapeutics and Vaccines.

Journal: Exploration (Beijing, China)

Published: May 10, 2024

Bioinformation Analysis of Differential Expression Proteins in Different Processes of COVID-19.

Bioinformation Analysis of Differential Expression Proteins in Different Processes of COVID-19.

Journal: Viral immunology

Published: May 08, 2024

Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.

Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.

Journal: Vaccine

Published: March 15, 2024

Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.

Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.

Journal: Vaccine

Published: August 10, 2023

Safety of an inactivated 2019-nCoV vaccine (Vero) in adults aged 60 years and older

Safety of an inactivated 2019-nCoV vaccine (Vero) in adults aged 60 years and older

Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Published: October 08, 2022

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.

Journal: The Lancet. Infectious diseases

Published: April 05, 2021

Immune response to different types of hepatitis B vaccine booster doses 2-32 years after the primary immunization schedule and its influencing factors.

Immune response to different types of hepatitis B vaccine booster doses 2-32 years after the primary immunization schedule and its influencing factors.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: December 05, 2019

Showing 1-12 of 12

Last Updated: 09/26/2026